Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, especially with a warm and shiny sun enveloping the Pharmalot campus, where the official mascots are fertilizing the newly manicured grounds and the short person has left for the summer job. As for us, we are considering our to-do list and brewing a needed cup of stimulation, since we anticipate another busy day. No doubt, you can relate. So time to get cracking. Here are some items of interest to get you started. Have a wonderful day and drop us a line when something interesting arises …

A Food and Drug Administration advisory panel voted 12 to 1 that the benefits of an experimental Johnson & Johnson medicine for rheumatoid arthritis do not outweigh the risks, Reuters reports. The panel did not recommend the drug be approved, citing safety concerns, including an imbalance in the number of deaths in patients compared with a placebo. The most common causes of death were major heart problems, infection, and malignancies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!